ArticleJournal of orthopaedic surgery and research2025
The role of radiotherapy and chemotherapy in extraskeletal myxoid chondrosarcoma.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExtraskeletal myxoid chondrosarcoma (EMC) is an extremely rare subtype of sarcoma characterized by NR4A3 gene rearrangement. Despite being considered slowly progressive sarcomas, EMCs tend to have local recurrences and distant metastases in the late stages. This study aimed to investigate the prognostic factors of EMCs, especially the effect of (neo)adjuvant radiotherapy or chemotherapy on localized EMCs and chemotherapy on advanced-stage EMCs.
methodsWe retrospectively analyzed 171 patients pathologically diagnosed with EMCs between 2002 and 2022 using the Japanese National Bone and Soft Tissue Tumor Registry Database.
resultsDisease-specific survival was significantly shorter in the group with distant metastasis at presentation (n = 29) than in the group without (n = 142) (5-year disease-specific survival, 75.8% [95% CI: 54.7-89.1] vs. 91.3% [95% CI: 83.0-95.8]; p = 0.012). Multivariate analysis showed that an R1 or R2 surgical margin was a risk factor for unfavorable local recurrence (hazard ratio [HR] 4.76 [95% CI: 1.72-13.15]; p = 0.003). No association was found between (neo)adjuvant radiotherapy and local recurrence rates. With respect to disease-specific survival, the tumor site of the trunk (HR 6.28 [95% CI: 1.30-30.49]; p = 0.023) and larger size (HR 1.18 [95% CI: 1.06-1.33]; p = 0.004) were risk factors for unfavorable disease-specific survival. No association was found between (neo)adjuvant, or advanced-stage chemotherapy and disease-specific survival rates.
conclusionsPatients with distant metastases at presentation had significantly shorter survival rates than those without. Wide resection is mandatory to reduce the risk of local recurrence of localized EMCs, and the local control effect of (neo)adjuvant radiotherapy is limited. Chemotherapy has a limited effect on improving survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.